# OnCo record xm01-22 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/xm01-22/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "xm01-22", "ISRCTN08063129" ;
  schema:name "XM01-22"@en ;
  schema:alternateName "XM01 22"@en, "ISRCTN08063129"@en ;
  schema:description "XM01-22 showed that a weekly injection of epoetin theta, a made-to-order copy of the hormone that tells the marrow to make red blood cells, lifted haemoglobin by a clear margin without a transfusion in almost three quarters of people on nonplatinum chemotherapy, against one quarter on placebo, which helped support its European approval for the anaemia of chemotherapy."@en ;
  schema:url <https://onco.cc/trials/xm01-22/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://www.isrctn.com/ISRCTN08063129>, <https://doi.org/10.1111/j.1753-5174.2011.00035.x>, <https://www.ema.europa.eu/en/medicines/human/EPAR/eporatio> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:drugs <https://onco.cc/drugs/epoetin-theta/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-xm01-22-tjulandin-arch-drug-inf-2011/> .